Dexamethasone Intravitreal Implant for Macular Edema Following Central Retinal Vein Occlusion


( Last Updated : July 12, 2022)
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA1222-000

Details


Question

  1. What is the clinical effectiveness of dexamethasone intravitreal implant versus no treatment or placebo for the treatment of macular edema following central retinal vein occlusion?
  2. What is the clinical effectiveness of dexamethasone intravitreal implant versus alternative interventions for the treatment of macular edema following central retinal vein occlusion?
  3. What is the cost-effectiveness of dexamethasone intravitreal implant versus no treatment or placebo for the treatment of macular edema following central retinal vein occlusion?
  4. What is the cost-effectiveness of dexamethasone intravitreal implant versus alternative interventions for the treatment of macular edema following central retinal vein occlusion?
  5. What are the evidence-based guidelines regarding?

Key Message

One non-randomized study was identified regarding the clinical effectiveness of dexamethasone intravitreal implant versus no treatment for the treatment of macular edema following central retinal vein occlusion.

One randomized controlled trial was identified regarding the clinical effectiveness of dexamethasone intravitreal implant versus alternative interventions for the treatment of macular edema following central retinal vein occlusion.

No economic evaluations were identified regarding the cost-effectiveness of dexamethasone intravitreal implant versus no treatment or placebo for the treatment of macular edema following central retinal vein occlusion.

No economic evaluations were identified regarding the cost-effectiveness of dexamethasone intravitreal implant versus alternative interventions for the treatment of macular edema following central retinal vein occlusion.

One evidence-based guideline was identified regarding the use of dexamethasone intravitreal implant for macular edema following central retinal vein occlusion.